MODAG is a privately held German biotech company that is revolutionizing the field of neurodegenerative disease treatment. They specialize in developing substances that directly target specific oligomer forms of proteins, preventing the pathological aggregation and formation of protein deposits. These deposits are known to cause neurodegenerative diseases such as MSA/Parkinson's, Alzheimer's, and Creutzfeldt-Jakob.

Headquartered in the Hochtechnologiepark Wendelsheim, Germany, MODAG also has research and development facilities in Munich and Göttingen. Their innovative approach combines early diagnosis with targeted disease-modifying therapies for severe neurological disorders. Collaborations with top-tier US and European research institutions, along with the expertise of MODAG's founder and management team, create an ideal environment for the accelerated implementation of their research into clinical applications.

MODAG focuses on developing a new oligomer modulator for Multiple System Atrophy (MSA) and other synucleinopathies like Parkinson's disease (PD). Their goal is to deliver novel disease-modifying, first-in-class drugs that have the potential to halt disease progression. At the helm of MODAG is Dr.

Torsten Matthias, the Chief Executive Officer, who brings over thirty years of experience in the biotech industry